



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 198148

TO: Shailendra Kumar
Location: 5c03 / 5c18
Tuesday, August 15, 2006
Art Unit: 1621
Phone: 571-272-0640
Serial Number: 10 / 541225

From: Jan Delaval
Location: Biotech-Chem Library
Remsen 1a51
Phone: 571-272-2504

jan.delaval@uspto.gov

Search Notes

=> fil reg

FILE 'REGISTRY' ENTERED AT 08:20:37 ON 15 AUG 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 14 AUG 2006 HIGHEST RN 901253-54-1
 DICTIONARY FILE UPDATES: 14 AUG 2006 HIGHEST RN 901253-54-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006


Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d sta que l32

L17 SCR 1926 OR 2019
 L18 SCR 2021
 L19 SCR 1126 OR 1149 OR 1164
 L20 SCR 1199 AND 1992
 L22 STR



VAR G1=4/10

VAR G2=O/S

VAR G3=O/S/N

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

L24 7731 SEA FILE=REGISTRY SSS FUL L22 AND L20 AND L19 AND (L18 OR L17)

L30 STR



VAR G1=4/10/23/40

VAR G2=O/S

VAR G3=O/S/N

VAR G4=S/SE

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 28

CONNECT IS E2 RC AT 32

CONNECT IS E2 RC AT 36

CONNECT IS E2 RC AT 44

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 35

STEREO ATTRIBUTES: NONE

L32 110 SEA FILE=REGISTRY SUB=L24 SSS FUL L30

100.0% PROCESSED 7731 ITERATIONS

110 ANSWERS

SEARCH TIME: 00.00.01

=> d sta que 137

L17 SCR 1926 OR 2019




L18 SCR 2021

L19 SCR 1126 OR 1149 OR 1164

L20 SCR 1199 AND 1992

L22

STR



VAR G1=4/10

VAR G2=O/S

VAR G3=O/S/N

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

L24 7731 SEA FILE=REGISTRY SSS FUL L22 AND L20 AND L19 AND (L18 OR L17)

L30 STR



VAR G1=4/10/23/40

VAR G2=O/S

VAR G3=O/S/N

VAR G4=S/SE

NODE ATTRIBUTES:


CONNECT IS E2 RC AT 28
 CONNECT IS E2 RC AT 32
 CONNECT IS E2 RC AT 36
 CONNECT IS E2 RC AT 44
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 35

STEREO ATTRIBUTES: NONE

L32 110 SEA FILE=REGISTRY SUB=L24 SSS FUL L30
 L33 STR



VAR G1=4/10
 VAR G2=O/S
 VAR G3=O/S/N
 VAR G4=S/SE

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 15
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE

L35 141 SEA FILE=REGISTRY SUB=L24 SSS FUL L33
 L37 154 SEA FILE=REGISTRY ABB=ON PLU=ON L32 OR L35

=> d his

(FILE 'HOME' ENTERED AT 07:24:29 ON 15 AUG 2006)
 SET COST OFF

FILE 'HCAPLUS' ENTERED AT 07:24:45 ON 15 AUG 2006

L1 1 S US20060069156/PN OR (US2005-541225# OR WO2004-FR319 OR FR2003
 E GENFIT/PA,CS
 L2 27 S E3-E13
 E DARTEIL/AU
 L3 20 S E4-E8
 E CAUMONT/AU
 L4 11 S E8,E14
 E BERTRAND/AU
 L5 5 S E3

L6 E BERTRAND K/AU
 8 S E3-E5,E7
 E NAJIB/AU
 L7 33 S E22,E24,E25
 SEL RN L1

FILE 'REGISTRY' ENTERED AT 07:29:49 ON 15 AUG 2006

L8 35 S E1-E35
 L9 9 S 733010-33-8 OR 733010-35-0 OR 733010-37-2 OR 733010-39-4 OR 7
 L10 1 S (733010-33-8 OR 733010-35-0 OR 733010-37-2 OR 733010-39-4 OR
 L11 10 S L9,L10
 L12 25 S L8 NOT L11
 L13 STR
 L14 1 S L13
 L15 STR L13
 L16 0 S L15
 L17 SCR 1926 OR 2019
 L18 SCR 2021
 L19 SCR 1126 OR 1149 OR 1164
 L20 SCR 1199 AND 1992
 L21 0 S L13 AND (L17 OR L18) AND L19 AND L20
 L22 STR L13
 L23 25 S L22 AND L20 AND L19 AND (L18 OR L17)
 L24 7731 S L22 AND L20 AND L19 AND (L18 OR L17) FUL
 SAV L24 KUMAR541/A TEMP
 L25 18 S L8 AND L24
 L26 8 S L25 NOT L11
 L27 5 S L26 NOT (C19H39NO3S OR C15H28N2O5S OR C12H21NO4S2)
 L28 15 S L11,L27
 L29 8 S L15 SAM SUB=L24
 L30 STR L15
 L31 7 S L30 SAM SUB=L24
 L32 110 S L30 FUL SUB=L24
 SAV L32 KUMAR541A/A
 L33 STR L22
 L34 9 S L33 SAM SUB=L24
 L35 141 S L33 FUL SUB=L24
 SAV L35 KUMAR541B/A
 L36 STR
 L37 154 S L32 OR L35
 L38 1 S L36 SAM SUB=L37
 L39 19 S L36 FUL SUB=L37
 SAV L39 KUMAR541C/A
 L40 135 S L37 NOT L39
 L41 120 S L40 NOT L28

FILE 'HCAOLD' ENTERED AT 08:02:34 ON 15 AUG 2006

L42 0 S L28
 L43 1 S L41
 SEL AN
 EDIT E36 /AN /OREF

FILE 'HCAPLUS' ENTERED AT 08:03:57 ON 15 AUG 2006

L44 1 S E36
 L45 3 S L28
 L46 42 S L41
 L47 1 S L44 AND L45,L46
 L48 3 S L45 AND L1-L7
 L49 2 S L46 AND L1-L7
 L50 31 S L46 AND (PD<=20030212 OR PRD<=20030212 OR AD<=20030212)

L51 0 S L41 (L) (THU OR PAC OR PKT OR DMA)/RL AND L50
L52 0 S L41 (L) BAC/RL AND L50
L53 14 S L50 AND (PHARMACEUT? OR PHARMACOL? OR BIOMOL? OR PATHOL? OR C
L54 16 S L50 AND P/DT
L55 24 S L53,L54
L56 7 S L50 NOT L55
SEL HIT RN L50

FILE 'REGISTRY' ENTERED AT 08:08:36 ON 15 AUG 2006

L57 62 S E37-E98
L58 58 S L41 NOT L57
L59 3 S L58 AND (C19H40N2OS2 OR C35H69NO2S4 OR C47H92N2O3S2)

FILE 'HCAOLD' ENTERED AT 08:17:01 ON 15 AUG 2006

L60 0 S L59

FILE 'HCAPLUS' ENTERED AT 08:17:04 ON 15 AUG 2006

L61 2 S L59
L62 4 S L47-L49,L61
L63 4 S L45,L62
SEL RN

FILE 'REGISTRY' ENTERED AT 08:19:24 ON 15 AUG 2006

L64 168 S E99-E266
L65 23 S L64 AND L24
L66 5 S L65 NOT L28,L59

FILE 'REGISTRY' ENTERED AT 08:20:37 ON 15 AUG 2006

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 08:20:57 ON 15 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Aug 2006 VOL 145 ISS 8
FILE LAST UPDATED: 14 Aug 2006 (20060814/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l63 bib abs hitstr retable tot

L63 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:650984 HCAPLUS
DN 141:190511
TI Preparation of acyl aminopropanediols as PPAR, in particular PPAR α ,

agonists and antioxidants for treating cerebral ischemia and related diseases

IN Darteil, Raphael; Caumont, Bertrand Karine;
Najib, Jamila

PA Genfit S. A., Fr.

SO Fr. Demande, 95 pp.



CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2850969	A1	20040813	FR 2003-1688	20030212 <--
	FR 2850969	B1	20050325		
	AU 2004213203	A1	20040902	AU 2004-213203	20040212 <--
	CA 2515680	AA	20040902	CA 2004-2515680	20040212 <--
	WO 2004074239	A1	20040902	WO 2004-FR319	20040212 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1592660	A1	20051109	EP 2004-710412	20040212 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1747928	A	20060315	CN 2004-80004024	20040212 <--
	JP 2006517570	T2	20060727	JP 2006-502143	20040212 <--
	US 2006069156	A1	20060330	US 2005-541225	20050701 <--
PRAI	FR 2003-1688	A	20030212	<--	
	WO 2004-FR319	W	20040212	<--	
OS	MARPAT 141:190511				
GI					




AB Title compds. I [wherein F, G = independently O, S, NR₄; F = G = NR₄ never possible; R, R₄ = independently H, (un)saturated (un)substituted alkyl; R₁, R₂, R₃ = independently H, C(:O)R₅, C(:O)(CH₂)_{2n+1}-X-R₆, with a least one of R₁, R₂, R₃ = C(:O)(CH₂)_{2n+1}-X-R₆; R₅ = (un)saturated (un)substituted (C₁-C₂₅) alkyl, optionally containing a cyclic group; X = S, Se, SO, SO₂; n = 0-11; R₆ = (un)saturated (un)substituted (C₃-C₂₃) alkyl, optionally containing

a cyclic group and/or O, S, Se, SO, SO₂; with the exclusion of compds. for which FR₂ = GR₃ = OH; their optical and geometrical isomers, racemates, salts, hydrates and mixts.] were prepared as peroxisome proliferator-activated receptors- α (PPAR α) agonists and antioxidants for treating cerebral ischemia and related diseases. For example, II was prepared in 3 steps from 1-bromotetradecane, mercaptoacetic acid, 3-aminopropane-1,2,-diol, and palmitic acid. In an antioxidant test, selected I diminished the formation of oxidation product of LDL by AAPH by 33%. Selected I were PPAR α agonists and showed induced luciferase activity via PPAR α /Gal4 transactivation. I are neuroprotectants useful for treating ischemia.

IT **733010-53-2P**, 1,3-Diamino-2-(tetradecylthioacetyloxy)propane dihydrochloride
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (PPAR α agonist; preparation of acyl aminopropanediols as PPAR agonists for treating ischemia)

RN **733010-53-2** HCAPLUS

CN Acetic acid, (tetradecylthio)-, 2-amino-1-(aminomethyl)ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

IT **733010-33-8P**, 1-[(Tetradecylthioacetyl)amino]-2,3-di[(palmitoyl)oxy]propane **733010-35-0P**, 3-[(Tetradecylthioacetyl)amino]-1,2-di[(tetradecylthioacetyl)oxy]propane **733010-37-2P**, 3-[(Palmitoyl)amino]-1,2-di[(tetradecylthioacetyl)oxy]propane **733010-39-4P**, 1,3-Di[(tetradecylthioacetyl)amino]propan-2-ol **733010-41-8P**, 1,3-Diamino-2-[[[(tetradecylthio)acetyl]oxy]propane **733010-44-1P**, 1,3-Di[(tetradecylthioacetyl)amino]-2-[(tetradecylthioacetyl)oxy]propane **733010-48-5P** **733010-54-3P**, 1,3-Di[(tetradecylthioacetyl)amino]-2-[(tetradecylthioacetyl)thio]propane **738604-36-9P**, 1,3-Dioleoylamino-2-(tetradecylthioacetyloxy)propane
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (PPAR α agonist; preparation of acyl aminopropanediols as PPAR agonists for treating ischemia)


RN **733010-33-8** HCAPLUS

CN Hexadecanoic acid, 1-[[[(tetradecylthio)acetyl]amino]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)




RN 733010-35-0 HCAPLUS

CN Acetic acid, (tetradecylthio)-, 1-[[[(tetradecylthio)acetyl]amino]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)




RN 733010-37-2 HCAPLUS

CN Acetic acid, (tetradecylthio)-, 1-[[[(1-oxohexadecyl)amino]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)




RN 733010-39-4 HCAPLUS

CN Acetamide, N,N'-(2-hydroxy-1,3-propanediyl)bis[2-(tetradecylthio)- (9CI) (CA INDEX NAME)]



RN 733010-41-8 HCAPLUS


CN Acetic acid, (tetradecylthio)-, 2-amino-1-(aminomethyl)ethyl ester (9CI) (CA INDEX NAME)



RN 733010-44-1 HCAPLUS


CN Acetic acid, (tetradecylthio)-, 2-[[[(tetradecylthio)acetyl]amino]-1-

[[[(tetradecylthio)acetyl]amino]methyl]ethyl ester (9CI) (CA INDEX NAME)




RN 733010-48-5 HCAPLUS

CN Ethanethioic acid, (tetradecylthio)-, S,S'-[1-
[[[(tetradecylthio)acetyl]amino]methyl]-1,2-ethanediyl] ester (9CI) (CA
INDEX NAME)



RN 733010-54-3 HCAPLUS

CN Ethanethioic acid, (tetradecylthio)-, S-[2-[[[(tetradecylthio)acetyl]amino]-
1-[[[(tetradecylthio)acetyl]amino]methyl]ethyl] ester (9CI) (CA INDEX
NAME)




RN 738604-36-9 HCAPLUS


CN Acetic acid, (tetradecylthio)-, 2-[[[(9Z)-1-oxo-9-octadecenyl]amino]-1-
[[[(9Z)-1-oxo-9-octadecenyl]amino]methyl]ethyl ester (9CI) (CA INDEX
NAME)

Double bond geometry as shown.


PAGE 1-A




PAGE 1-B




IT 733010-52-1P, 1,3-Di[(tert-butyloxycarbonyl)amino]-2-
 [[(tetradecylthio)acetyl]oxy]propane 733010-56-5P,
 1,3-Di[(tert-butyloxycarbonyl)amino]-2-[(tetradecylthioacetyl)thio]propane
 733010-61-2P, 1-[(tert-Butyloxycarbonyl)amino]-2,3-
 di[[[(tetradecylthio)acetyl]thio]propane 736992-56-6P,
 1-Amino-2,3-di[[[(tetradecylthio)acetyl]thio]propane hydrochloride
 738604-37-0P, 1,3-Diamino-2-(tetradecylthioacetylthio)propane
 dihydrochloride
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of acyl aminopropanediols as PPAR agonists for
 treating ischemia)
 RN 733010-52-1 HCAPLUS
 CN Acetic acid, (tetradecylthio)-, 2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-
 [[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]ethyl ester (9CI) (CA INDEX
 NAME)



RN 733010-56-5 HCAPLUS
 CN Ethanethioic acid, (tetradecylthio)-, S-[2-[[[(1,1-
 dimethylethoxy)carbonyl]amino]-1-[[[(1,1-dimethylethoxy)carbonyl]amino]met
 hyl]ethyl] ester (9CI) (CA INDEX NAME)




RN 733010-61-2 HCAPLUS
 CN Ethanethioic acid, (tetradecylthio)-, S,S'-[1-[[[(1,1-
 dimethylethoxy)carbonyl]amino]methyl]-1,2-ethanediyl] ester (9CI) (CA
 INDEX NAME)



RN 736992-56-6 HCAPLUS


CN Ethanethioic acid, (tetradecylthio)-, S,S'-[1-(aminomethyl)-1,2-ethanediy] ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 738604-37-0 HCAPLUS

CN Ethanethioic acid, (tetradecylthio)-, S-[2-amino-1-(aminomethyl)ethyl] ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Johns Hopkins Universit	1999			WO 9910321 A	HCAPLUS
Rahman, M	1988	31	1656	Journal of Medicinal	HCAPLUS
Sankyo	2000			JP 2000169443 A	HCAPLUS

L63 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:650967 HCAPLUS

DN 141:185113

TI Therapeutic use of acyl glycerols and their nitrogen and sulfur analogs

IN Darteil, Raphael; Caumont, Bertrand Karine;

Najib, Jamila

PA Genfit S. A., Fr.

SO Fr. Demande, 144 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

jan delaval - 15 august 2006

PI FR 2850870 A1 20040813 FR 2003-1691 20030212
 FR 2850870 B1 20060728
 WO 2004073698 A1 20040902 WO 2004-FR322 20040212

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
 BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
 MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG

EP 1596845 A1 20051123 EP 2004-710415 20040212
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

US 2006154984 A1 20060713 US 2005-542512 20050718
 PRAI FR 2003-1691 A 20030212
 WO 2004-FR322 W 20040212

OS MARPAT 141:185113

AB The invention discloses the use of acyl glycerols and their nitrogen and sulfur analogs for the therapy and in particular in human health. The compds. of the invention have advantageous pharmacol. properties and are in particular usable for the prevention and treatment of neurodegenerative diseases.

IT 733010-33-8P 733010-35-0P 733010-37-2P


733010-39-4P 733010-46-3P 733010-48-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(acyl glycerols and nitrogen and sulfur analogs for therapeutic use)


RN 733010-33-8 HCAPLUS

CN Hexadecanoic acid, 1-[[[(tetradecylthio)acetyl]amino]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)




RN 733010-35-0 HCAPLUS

CN Acetic acid, (tetradecylthio)-, 1-[[[(tetradecylthio)acetyl]amino]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)




RN 733010-37-2 HCAPLUS

CN Acetic acid, (tetradecylthio)-, 1-[[[(1-oxohexadecyl)amino]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)




RN 733010-39-4 HCAPLUS

CN Acetamide, N,N'-(2-hydroxy-1,3-propanediyl)bis[2-(tetradecylthio)- (9CI)
(CA INDEX NAME)


RN 733010-46-3 HCAPLUS

CN Ethanethioic acid, (tetradecylthio)-, S-[2-[(1-oxotetradecyl)amino]-1-[[1-oxotetradecyl)amino]methyl]ethyl] ester (9CI) (CA INDEX NAME)



RN 733010-48-5 HCAPLUS

CN Ethanethioic acid, (tetradecylthio)-, S,S'-[1-[[[(tetradecylthio)acetyl]amino]methyl]-1,2-ethanediyl] ester (9CI) (CA INDEX NAME)




IT 733010-41-8 733010-44-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(acyl glycerols and nitrogen and sulfur analogs for therapeutic use)


RN 733010-41-8 HCAPLUS

CN Acetic acid, (tetradecylthio)-, 2-amino-1-(aminomethyl)ethyl ester (9CI)
(CA INDEX NAME)



RN 733010-44-1 HCAPLUS

CN Acetic acid, (tetradecylthio)-, 2-[[[(tetradecylthio)acetyl]amino]-1-[[[(tetradecylthio)acetyl]amino]methyl]ethyl ester (9CI) (CA INDEX NAME)



IT 733010-52-1P 733010-53-2P 733010-56-5P


733010-57-6P 733010-61-2P 733010-62-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(acyl glycerols and nitrogen and sulfur analogs for therapeutic use)


RN 733010-52-1 HCAPLUS

CN Acetic acid, (tetradecylthio)-, 2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]ethyl ester (9CI) (CA INDEX NAME)



RN 733010-53-2 HCAPLUS


CN Acetic acid, (tetradecylthio)-, 2-amino-1-(aminomethyl)ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 733010-56-5 HCAPLUS

CN Ethanethioic acid, (tetradecylthio)-, S-[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]ethyl] ester (9CI) (CA INDEX NAME)




RN 733010-57-6 HCAPLUS

CN Ethanethioic acid, (tetradecylthio)-, S-[2-amino-1-(aminomethyl)ethyl] ester (9CI) (CA INDEX NAME)




RN 733010-61-2 HCAPLUS

CN Ethanethioic acid, (tetradecylthio)-, S,S'-[1-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-1,2-ethanediyl] ester (9CI) (CA INDEX NAME)



RN 733010-62-3 HCAPLUS

CN Ethanethioic acid, (tetradecylthio)-, S,S'-[1-(aminomethyl)-1,2-ethanediyl] ester (9CI) (CA INDEX NAME)




IT 733010-54-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(acyl glycerols and nitrogen and sulfur analogs for therapeutic use)

RN 733010-54-3 HCAPLUS

CN Ethanethioic acid, (tetradecylthio)-, S-[2-[[[(tetradecylthio)acetyl]amino]-1-[[[(tetradecylthio)acetyl]amino]methyl]ethyl] ester (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Calabrese, V	2001	26	739	NEUROCHEMICAL RESEAR	HCAPLUS
Combs, C	2001	39	449	NEUROCHEMISTRY INTER	HCAPLUS
Markesbery, W	1999	9	133	BRAIN PATHOLOGY	HCAPLUS

L63 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:650966 HCAPLUS

DN 141:200217

TI Acyl aminopropanediols and their nitrogen and sulfur analogs, their preparation, and their therapeutic and cosmetic use

IN **Najib, Jamila**PA **Genfit S. A., Fr.**

SO Fr. Demande, 114 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2850869	A1	20040813	FR 2003-1689	20030212
	FR 2850869	B1	20050325		
	CA 2515480	AA	20040902	CA 2004-2515480	20040212
	WO 2004073593	A2	20040902	WO 2004-FR320	20040212
	WO 2004073593	A3	20041118		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW, BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1594486	A2	20051116	EP 2004-710413	20040212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006518358	T2	20060810	JP 2006-502144	20040212
	US 2006035977	A1	20060216	US 2005-542056	20050921
PRAI	FR 2003-1689	A	20030212		
	WO 2004-FR320	W	20040212		

OS MARPAT 141:200217

AB The invention discloses the use of mols., in particular in the fields of human and animal health and cosmetics. The compds. of the invention are acyl aminopropanediols, and their nitrogen and sulfur analogs, having advantageous pharmacol. and cosmetic properties. The compds. of the invention are usable in particular to prevent and/or treat cardiovascular diseases, dyslipidemias, syndrome X, restenosis, diabetes, obesity, hypertension, cancer, and dermatol. diseases, as well as in cosmetics to

fight against skin aging and its effects in particular against the appearance of wrinkles.


IT 733010-33-8P 733010-37-2P 733010-39-4P
733010-44-1P 733010-46-3P 733010-48-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(acyl aminopropanediols and analogs, preparation, and therapeutic and cosmetic use)


RN 733010-33-8 HCAPLUS

CN Hexadecanoic acid, 1-[[[(tetradecylthio)acetyl]amino]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)




RN 733010-37-2 HCAPLUS

CN Acetic acid, (tetradecylthio)-, 1-[[[(1-oxohexadecyl)amino]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)




RN 733010-39-4 HCAPLUS

CN Acetamide, N,N'-(2-hydroxy-1,3-propanediyl)bis[2-(tetradecylthio)- (9CI) (CA INDEX NAME)]




RN 733010-44-1 HCAPLUS

CN Acetic acid, (tetradecylthio)-, 2-[[[(tetradecylthio)acetyl]amino]-1-[[[(tetradecylthio)acetyl]amino]methyl]ethyl ester (9CI) (CA INDEX NAME)]




RN 733010-46-3 HCAPLUS

CN Ethanethioic acid, (tetradecylthio)-, S-[2-[(1-oxotetradecyl)amino]-1-[(1-oxotetradecyl)amino]methyl]ethyl] ester (9CI) (CA INDEX NAME)



RN 733010-48-5 HCAPLUS

CN Ethanethioic acid, (tetradecylthio)-, S,S'-[1-[[[(tetradecylthio)acetyl]amino]methyl]-1,2-ethanediyl] ester (9CI) (CA INDEX NAME)




IT 733010-41-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(acyl aminopropanediols and analogs, preparation, and therapeutic and cosmetic use)

RN 733010-41-8 HCAPLUS

CN Acetic acid, (tetradecylthio)-, 2-amino-1-(aminomethyl)ethyl ester (9CI) (CA INDEX NAME)




IT 733010-52-1P 733010-56-5P 733010-57-6P

733010-61-2P 736992-56-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(acyl aminopropanediols and analogs, preparation, and therapeutic and cosmetic use)


RN 733010-52-1 HCAPLUS

CN Acetic acid, (tetradecylthio)-, 2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]ethyl] ester (9CI) (CA INDEX NAME)




RN 733010-56-5 HCAPLUS

CN Ethanethioic acid, (tetradecylthio)-, S-[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]ethyl] ester (9CI) (CA INDEX NAME)




RN 733010-57-6 HCAPLUS

CN Ethanethioic acid, (tetradecylthio)-, S-[2-amino-1-(aminomethyl)ethyl] ester (9CI) (CA INDEX NAME)




RN 733010-61-2 HCAPLUS

CN Ethanethioic acid, (tetradecylthio)-, S,S'-[1-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-1,2-ethanediyl] ester (9CI) (CA INDEX NAME)



RN 736992-56-6 HCAPLUS

CN Ethanethioic acid, (tetradecylthio)-, S,S'-[1-(aminomethyl)-1,2-ethanediyl] ester, hydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 733010-53-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(acyl aminopropanediols and analogs, preparation, and therapeutic and cosmetic use)

RN 733010-53-2 HCAPLUS

CN Acetic acid, (tetradecylthio)-, 2-amino-1-(aminomethyl)ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Kuhajda, F	1999			WO 9910321 A	HCAPLUS

L63 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1963:408508 HCAPLUS

DN 59:8508

OREF 59:1479h,1480a-e

TI Enzyme-alterable alkylating agents. I. Synthesis, chemical properties, and toxicities of sulfur mustards containing enzyme-susceptible amide bonds

AU Witten, Benjamin; Williamson, Charles E.; Sass, Samuel; Miller, Jacob I.; Best, Roland; Wicks, George E., Jr.; Kramer, Stanley P.; Weinberg, Tobias; Solomon, Robert D.; Goodman, Louis E.; Seligman, Arnold M.

CS Sinai Hosp., Baltimore, MD

SO Cancer (1962), 15, 1041-55


DT Journal

LA Unavailable

AB A number of polyfunctional and monofunctional alkylating agents were synthesized in an attempt to develop carcinolytic compds. that would take advantage of reported differences in enzyme activity (e.g., esterase, amidase, and phosphamidase) between carcinoma and vital normal tissue. To take advantage of the situation wherein amidase is relatively low in tumor tissue, bifunctional amides of the general structure $\text{ClCH}_2\text{CH}_2\text{S}(\text{CH}_2)_n\text{CONH}(\text{CH}_2)_x\text{NHCO}(\text{CH}_2)_n\text{SCH}_2\text{CH}_2\text{Cl}$ were compared with their monofunctional enzyme breakdown products as well as with other structurally related compds. Two methods of synthesis were employed. In one procedure, the appropriate amine in aqueous NaOH was treated with the desired acyl chloride at 0°, the precipitate filtered off and recrystd., treated with NaSCH₂CH₂OH to yield the alc. intermediate, which was converted to the sulfur mustard by gentle treatment with SOCl₂. In the


other procedure, a monofunctional sulfur mustard carboxylic acid was prepared by irradiating with ultraviolet light a mixture of the appropriate mercaptocarboxylic acid and $\text{CH}_2:\text{CHCl}$ in the presence of a catalyst. Treatment with SOCl_2 yielded an acid chloride, which was treated with the appropriate amine in CHCl_3 with an excess of Na_2CO_3 to yield the sulfur mustard. Compds. synthesized included the chloro amides, $(\text{ClCH}_2\text{CONHCH}_2)_2\text{CH}_2$, $(\text{ClCH}_2\text{CONHCH}_2)_2$, $(\text{ClCH}_2\text{CH}_2\text{CONHCH}_2)_2$, $(\text{ClCH}_2\text{CONHCH}_2\text{CH}_2)_2\text{CH}_2$, and $(\text{ClCH}_2\text{CH}_2\text{CONHCH}_2\text{CH}_2)_2$; the hydroxy amides, $\text{HOCH}_2\text{CH}_2\text{SCH}_2\text{CONHMe}$, $(\text{HOCH}_2\text{CH}_2\text{SCH}_2\text{CONHCH}_2)_2$, $(\text{HOCH}_2\text{CH}_2\text{SCH}_2\text{CH}_2\text{CONHCH}_2)_2$, and $(\text{HOCH}_2\text{CH}_2\text{SCH}_2\text{CH}_2\text{CONHCH}_2\text{CH}_2)_2$; the sulfur mustards, $(\text{ClCH}_2\text{CH}_2\text{SCH}_2\text{CONHCH}_2)_2$, $(\text{ClCH}_2\text{CH}_2\text{SCH}_2\text{CONHCH}_2)_2\text{CHOH}$, $(\text{ClCH}_2\text{CH}_2\text{SCH}_2\text{CH}_2\text{CONHCH}_2)_2$, $(\text{ClCH}_2\text{CH}_2\text{SCH}_2\text{CONHCH}_2)_2\text{CH}_2$, $(\text{ClCH}_2\text{CH}_2\text{SCH}_2\text{CONHCH}_2\text{CH}_2)_2$, $(\text{ClCH}_2\text{CH}_2\text{SCH}_2\text{CH}_2\text{CONHCH}_2)_2\text{CHOH}$, $(\text{ClCH}_2\text{CH}_2\text{SCH}_2\text{CH}_2\text{CONHCH}_2\text{CH}_2)_2$, $(\text{ClCH}_2\text{CH}_2\text{SCH}_2\text{CONHCH}_2\text{CH}_2)_2\text{CH}_2$, $\text{ClCH}_2\text{CH}_2\text{SCH}_2\text{CO}_2\text{H}$, $\text{ClCH}_2\text{CH}_2\text{SCH}_2\text{CONHMe}$, $\text{ClCH}_2\text{CH}_2\text{SCH}_2\text{CH}_2\text{CO}_2\text{H}$, and $\text{ClCH}_2\text{CH}_2\text{SCH}_2\text{COCl}$. Hydrolysis of these compds. at the C-Cl bond and the amide link was studied under various conditions. Hydrolysis of the amide link occurred only in the chlorine-containing compds. and not in the glycols. Comparisons of toxicities were encouraging in that the bifunctional compds. were much more toxic both to dogs and mice than were their monofunctional products. Furthermore, the ratio of toxicity of the bifunctional compound to its products was greater in dogs than in mice. This is in agreement with the lower serum amidase activity of dogs. Further interest in these agents was provided by the possibility of developing cytotoxic but rapidly hydrolyzing and detoxifying bifunctional agents for use in intra-arterial chemotherapy. 51 references.

IT 91354-85-7, Acetamide, N,N'-(2-hydroxytrimethylene)bis[2-[(2-chloroethyl)thio]-
 91972-62-2, Propionamide, N,N'-(2-hydroxytrimethylene)bis[3-[(2-chloroethyl)thio]-
 (preparation of)
 RN 91354-85-7 HCAPLUS
 CN Acetamide, N,N'-(2-hydroxytrimethylene)bis[2-[(2-chloroethyl)thio]- (7CI)
 (CA INDEX NAME)




RN 91972-62-2 HCAPLUS
 CN Propionamide, N,N'-(2-hydroxytrimethylene)bis[3-[(2-chloroethyl)thio]-
 (7CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



=> => fil uspatful

FILE 'USPATFULL' ENTERED AT 08:21:55 ON 15 AUG 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 15 Aug 2006 (20060815/PD)

FILE LAST UPDATED: 15 Aug 2006 (20060815/ED)

HIGHEST GRANTED PATENT NUMBER: US7093300

HIGHEST APPLICATION PUBLICATION NUMBER: US2006179536

CA INDEXING IS CURRENT THROUGH 15 Aug 2006 (20060815/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 15 Aug 2006 (20060815/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2006

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2006

=> d his l67

(FILE 'REGISTRY' ENTERED AT 08:19:24 ON 15 AUG 2006)

FILE 'REGISTRY' ENTERED AT 08:20:37 ON 15 AUG 2006

FILE 'HCAPLUS' ENTERED AT 08:20:57 ON 15 AUG 2006

FILE 'USPATFULL' ENTERED AT 08:21:32 ON 15 AUG 2006
L67 3 S L59 OR L28

FILE 'USPATFULL' ENTERED AT 08:21:55 ON 15 AUG 2006

=> d bib abs hitstr tot

L67 ANSWER 1 OF 3 USPATFULL on STN

AN 2006:182580 USPATFULL

TI Therapeutic use of acyl glycerols and the nitrogen- and sulphur-
containing analogues thereof

IN Darteil, Raphael, Lille, FRANCE

Caumont-Bertrand, Karine, Frelinghien, FRANCE

Najib, Jamila, Santes, FRANCE

PI US 2006154984 A1 20060713

AI US 2004-542512 A1 20040212 (10)

WO 2004-FR322 20040212

20050718 PCT 371 date

PRAI FR 2003-1691 20030212

DT Utility

FS APPLICATION

LREP NIXON & VANDERHYE, PC, 901 NORTH GLEBE ROAD, 11TH FLOOR, ARLINGTON, VA,
22203, US

CLMN Number of Claims: 25

ECL Exemplary Claim: 1-24

DRWN 6 Drawing Page(s)

LN.CNT 4597

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of acyl glycerols and the nitrogen- and
sulfur-containing analogues thereof in the therapeutic field,
particularly in human health. The inventive compounds have advantageous
pharmacological properties and are particularly of use for the
prevention or treatment of neurodegenerative diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 733010-33-8P 733010-35-0P 733010-37-2P


jan delaval - 15 august 2006

733010-39-4P 733010-46-3P 733010-48-5P

(acyl glycerols and nitrogen and sulfur analogs for therapeutic use)


RN 733010-33-8 USPATFULL

CN Hexadecanoic acid, 1-[[[(tetradecylthio)acetyl]amino]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)




RN 733010-35-0 USPATFULL

CN Acetic acid, (tetradecylthio)-, 1-[[[(tetradecylthio)acetyl]amino]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)




RN 733010-37-2 USPATFULL

CN Acetic acid, (tetradecylthio)-, 1-[[[(1-oxohexadecyl)amino]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)




RN 733010-39-4 USPATFULL

CN Acetamide, N,N'-(2-hydroxy-1,3-propanediyl)bis[2-(tetradecylthio)- (9CI) (CA INDEX NAME)




RN 733010-46-3 USPATFULL

CN Ethanethioic acid, (tetradecylthio)-, S-[2-[(1-oxotetradecyl)amino]-1-[[[(1-oxotetradecyl)amino]methyl]ethyl] ester (9CI) (CA INDEX NAME)




RN 733010-48-5 USPATFULL

CN Ethanethioic acid, (tetradecylthio)-, S,S'-[1-
[[[(tetradecylthio)acetyl]amino]methyl]-1,2-ethanediyl] ester (9CI) (CA
INDEX NAME)


IT 733010-41-8 733010-44-1

(acyl glycerols and nitrogen and sulfur analogs for therapeutic use)

RN 733010-41-8 USPATFULL

CN Acetic acid, (tetradecylthio)-, 2-amino-1-(aminomethyl)ethyl ester (9CI)
(CA INDEX NAME)

RN 733010-44-1 USPATFULL

CN Acetic acid, (tetradecylthio)-, 2-[[[(tetradecylthio)acetyl]amino]-1-
[[[(tetradecylthio)acetyl]amino]methyl]ethyl ester (9CI) (CA INDEX
NAME)


IT 733010-52-1P 733010-53-2P 733010-56-5P

733010-57-6P 733010-61-2P 733010-62-3P

(acyl glycerols and nitrogen and sulfur analogs for therapeutic use)


RN 733010-52-1 USPATFULL

CN Acetic acid, (tetradecylthio)-, 2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-
[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]ethyl ester (9CI) (CA
INDEX NAME)



RN 733010-53-2 USPATFULL


CN Acetic acid, (tetradecylthio)-, 2-amino-1-(aminomethyl)ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 733010-56-5 USPATFULL

CN Ethanethioic acid, (tetradecylthio)-, S-[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]ethyl] ester (9CI) (CA INDEX NAME)




RN 733010-57-6 USPATFULL

CN Ethanethioic acid, (tetradecylthio)-, S-[2-amino-1-(aminomethyl)ethyl] ester (9CI) (CA INDEX NAME)




RN 733010-61-2 USPATFULL

CN Ethanethioic acid, (tetradecylthio)-, S,S'-[1-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-1,2-ethanediyl] ester (9CI) (CA INDEX NAME)



RN 733010-62-3 USPATFULL

CN Ethanethioic acid, (tetradecylthio)-, S,S'-[1-(aminomethyl)-1,2-ethanediyl] ester (9CI) (CA INDEX NAME)




IT 733010-54-3P

(acyl glycerols and nitrogen and sulfur analogs for therapeutic use)

RN 733010-54-3 USPATFULL

CN Ethanethioic acid, (tetradecylthio)-, S-[2-[[[(tetradecylthio)acetyl]amino]-1-[[[(tetradecylthio)acetyl]amino]methyl]ethyl] ester (9CI) (CA INDEX NAME)



L67 ANSWER 2 OF 3 USPATFULL on STN

AN 2006:81160 USPATFULL

TI Acylated aminopropanediols and analogues and therapeutic uses thereof

IN Darteil, Raphael, Lille, FRANCE

Caumont-Bertrand, Karine, Frelinghien, FRANCE

Najib, Jamila, Santes, FRANCE

PI US 2006069156 A1 20060330

AI US 2004-541225 A1 20040212 (10)

WO 2004-FR319 20040212

20050701 PCT 371 date

PRAI FR 2003-1688 20030212

DT Utility

FS APPLICATION

LREP NIXON & VANDERHYE, PC, 901 NORTH GLEBE ROAD, 11TH FLOOR, ARLINGTON, VA, 22203, US

CLMN Number of Claims: 17

ECL Exemplary Claim: 1-17

DRWN 3 Drawing Page(s)

LN.CNT 2995


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel acylated aminopropanediols and the nitrogen and sulfur analogues thereof, pharmaceutical compositions

comprising same, therapeutic uses thereof, in particular for the treatment of cerebral ischemia. The invention also provides a method of preparing said derivatives.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 733010-53-2P, 1,3-Diamino-2-(tetradecylthioacetyloxy)propane dihydrochloride
(PPAR α agonist; preparation of acyl aminopropanediols as PPAR agonists for treating ischemia)
RN 733010-53-2 USPATFULL
CN Acetic acid, (tetradecylthio)-, 2-amino-1-(aminomethyl)ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

IT 733010-33-8P, 1-[(Tetradecylthioacetyl)amino]-2,3-di[(palmitoyl)oxy]propane 733010-35-0P, 3-[(Tetradecylthioacetyl)amino]-1,2-di[(tetradecylthioacetyl)oxy]propane 733010-37-2P, 3-[(Palmitoyl)amino]-1,2-di[(tetradecylthioacetyl)oxy]propane 733010-39-4P, 1,3-Di[(tetradecylthioacetyl)amino]propan-2-ol 733010-41-8P, 1,3-Diamino-2-[[[(tetradecylthio)acetyl]oxy]propane 733010-44-1P, 1,3-Di[(tetradecylthioacetyl)amino]-2-[(tetradecylthioacetyl)oxy]propane 733010-48-5P 733010-54-3P, 1,3-Di[(tetradecylthioacetyl)amino]-2-[(tetradecylthioacetyl)thio]propane 738604-36-9P, 1,3-Dioleoylamino-2-(tetradecylthioacetyloxy)propane
(PPAR α agonist; preparation of acyl aminopropanediols as PPAR agonists for treating ischemia)
RN 733010-33-8 USPATFULL
CN Hexadecanoic acid, 1-[[[(tetradecylthio)acetyl]amino]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)




RN 733010-35-0 USPATFULL
CN Acetic acid, (tetradecylthio)-, 1-[[[(tetradecylthio)acetyl]amino]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)




RN 733010-37-2 USPATFULL

CN Acetic acid, (tetradecylthio)-, 1-[[[(1-oxohexadecyl)amino]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)




RN 733010-39-4 USPATFULL

CN Acetamide, N,N'-(2-hydroxy-1,3-propanediyl)bis[2-(tetradecylthio)- (9CI) (CA INDEX NAME)]




RN 733010-41-8 USPATFULL

CN Acetic acid, (tetradecylthio)-, 2-amino-1-(aminomethyl)ethyl ester (9CI) (CA INDEX NAME)




RN 733010-44-1 USPATFULL

CN Acetic acid, (tetradecylthio)-, 2-[[[(tetradecylthio)acetyl]amino]-1-[[[(tetradecylthio)acetyl]amino]methyl]ethyl ester (9CI) (CA INDEX NAME)]




RN 733010-48-5 USPATFULL

CN Ethanethioic acid, (tetradecylthio)-, S,S'-[1-
 [[[(tetradecylthio)acetyl]amino]methyl]-1,2-ethanediyl] ester (9CI) (CA
 INDEX NAME)



RN 733010-54-3 USPATFULL

CN Ethanethioic acid, (tetradecylthio)-, S-[2-[[[(tetradecylthio)acetyl]amino]-
 1-[[[(tetradecylthio)acetyl]amino]methyl]ethyl] ester (9CI) (CA INDEX
 NAME)




RN 738604-36-9 USPATFULL


CN Acetic acid, (tetradecylthio)-, 2-[[[(9Z)-1-oxo-9-octadecenyl]amino]-1-
 [[[(9Z)-1-oxo-9-octadecenyl]amino]methyl]ethyl ester (9CI) (CA INDEX
 NAME)

Double bond geometry as shown.


PAGE 1-A




PAGE 1-B




- IT 733010-52-1P, 1,3-Di[(tert-butyloxycarbonyl)amino]-2-
 [[(tetradecylthio)acetyl]oxy]propane 733010-56-5P,
 1,3-Di[(tert-butyloxycarbonyl)amino]-2-[(tetradecylthioacetyl)thio]propan
 e 733010-61-2P, 1-[(tert-Butyloxycarbonyl)amino]-2,3-
 di[(tetradecylthio)acetyl]thio]propane 736992-56-6P,
 1-Amino-2,3-di[(tetradecylthio)acetyl]thio]propane hydrochloride
 738604-37-0P, 1,3-Diamino-2-(tetradecylthioacetylthio)propane
 dihydrochloride
 (intermediate; preparation of acyl aminopropanediols as PPAR agonists for
 treating ischemia)
- RN 733010-52-1 USPATFULL
- CN Acetic acid, (tetradecylthio)-, 2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-
 [[[(1,1-dimethylethoxy)carbonyl]amino]methyl]ethyl ester (9CI) (CA
 INDEX NAME)




- RN 733010-56-5 USPATFULL
- CN Ethanethioic acid, (tetradecylthio)-, S-[2-[[[(1,1-
 dimethylethoxy)carbonyl]amino]-1-[[[(1,1-dimethylethoxy)carbonyl]amino]m
 ethyl]ethyl] ester (9CI) (CA INDEX NAME)



- RN 733010-61-2 USPATFULL
- CN Ethanethioic acid, (tetradecylthio)-, S,S'-[1-[[[(1,1-
 dimethylethoxy)carbonyl]amino]methyl]-1,2-ethanediyl] ester (9CI) (CA
 INDEX NAME)




- RN 736992-56-6 USPATFULL
- CN Ethanethioic acid, (tetradecylthio)-, S,S'-[1-(aminomethyl)-1,2-
 ethanediyl] ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 738604-37-0 USPATFULL

CN Ethanethioic acid, (tetradecylthio)-, S-[2-amino-1-(aminomethyl)ethyl]
ester, dihydrochloride (9CI) (CA INDEX NAME)

● 2 HCl

L67 ANSWER 3 OF 3 USPATFULL on STN

AN 2006:41325 USPATFULL

TI Uses of acylated aminopropanediols and sulphur and nitrogen analogues of
same f

IN Najib, Jamila, Santes, FRANCE

PA Gentif, Loos, FRANCE, F-59120 (non-U.S. corporation)

PI US 2006035977 A1 20060216

AI US 2003-542056 A1 20040212 (10)

WO 2004-FR320 20040212

20050921 PCT 371 date

PRAI FR 2003-1689 20030212

DT Utility

FS APPLICATION

LREP NIXON & VANDERHYE, PC, 901 NORTH GLEBE ROAD, 11TH FLOOR, ARLINGTON, VA,
22203, US

CLMN Number of Claims: 19

ECL Exemplary Claim: 1-18

DRWN 4 Drawing Page(s)

LN.CNT 3511

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of molecules, particularly in the fields of human and veterinary health and cosmetics. The inventive compounds are acylated aminopropanediols and the nitrogen- and sulfur-containing analogues thereof and have advantageous pharmacological and cosmetic properties. In particular, the inventive compounds can be used to prevent and/or treat dyslipidemias, cardiovascular diseases, syndrome X, restenosis, diabetes, obesity, hypertension, some cancers, dermatological diseases, and, in the field of cosmetics, to combat skin ageing and the effects of same, in particular the development of wrinkles and the like.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 733010-33-8P 733010-37-2P 733010-39-4P


733010-44-1P 733010-46-3P 733010-48-5P

(acyl aminopropanediols and analogs, preparation, and therapeutic and cosmetic use)


RN 733010-33-8 USPATFULL
 CN Hexadecanoic acid, 1-[[[(tetradecylthio)acetyl]amino]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)




RN 733010-37-2 USPATFULL
 CN Acetic acid, (tetradecylthio)-, 1-[[[(1-oxohexadecyl)amino]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)




RN 733010-39-4 USPATFULL
 CN Acetamide, N,N'-(2-hydroxy-1,3-propanediyl)bis[2-(tetradecylthio)- (9CI) (CA INDEX NAME)]




RN 733010-44-1 USPATFULL
 CN Acetic acid, (tetradecylthio)-, 2-[[[(tetradecylthio)acetyl]amino]-1-[[[(tetradecylthio)acetyl]amino]methyl]ethyl ester (9CI) (CA INDEX NAME)]



RN 733010-46-3 USPATFULL
 CN Ethanethioic acid, (tetradecylthio)-, S-[2-[(1-oxotetradecyl)amino]-1-[[[(1-oxotetradecyl)amino]methyl]ethyl] ester (9CI) (CA INDEX NAME)]




RN 733010-48-5 USPATFULL

CN Ethanethioic acid, (tetradecylthio)-, S,S'-[1-
[[[(tetradecylthio)acetyl]amino]methyl]-1,2-ethanediyl] ester (9CI) (CA
INDEX NAME)

IT 733010-41-8

(acyl aminopropanediols and analogs, preparation, and therapeutic and
cosmetic use)

RN 733010-41-8 USPATFULL


CN Acetic acid, (tetradecylthio)-, 2-amino-1-(aminomethyl)ethyl ester (9CI)
(CA INDEX NAME)

IT 733010-52-1P 733010-56-5P 733010-57-6P

733010-61-2P 736992-56-6P

(acyl aminopropanediols and analogs, preparation, and therapeutic and
cosmetic use)


RN 733010-52-1 USPATFULL

CN Acetic acid, (tetradecylthio)-, 2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-
[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]ethyl ester (9CI) (CA
INDEX NAME)

RN 733010-56-5 USPATFULL


CN Ethanethioic acid, (tetradecylthio)-, S-[2-[[[(1,1-
dimethylethoxy)carbonyl]amino]-1-[[[(1,1-dimethylethoxy)carbonyl]amino]m

ethyl]ethyl] ester (9CI) (CA INDEX NAME)




RN 733010-57-6 USPATFULL

CN Ethanethioic acid, (tetradecylthio)-, S-[2-amino-1-(aminomethyl)ethyl] ester (9CI) (CA INDEX NAME)




RN 733010-61-2 USPATFULL

CN Ethanethioic acid, (tetradecylthio)-, S,S'-[1-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-1,2-ethanediyl] ester (9CI) (CA INDEX NAME)



RN 736992-56-6 USPATFULL

CN Ethanethioic acid, (tetradecylthio)-, S,S'-[1-(aminomethyl)-1,2-ethanediyl] ester, hydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 733010-53-2P

(acyl aminopropanediols and analogs, preparation, and therapeutic and cosmetic use)

RN 733010-53-2 USPATFULL

CN Acetic acid, (tetradecylthio)-, 2-amino-1-(aminomethyl)ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

=> d his

(FILE 'HOME' ENTERED AT 07:24:29 ON 15 AUG 2006)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 07:24:45 ON 15 AUG 2006

L1 1 S US20060069156/PN OR (US2005-541225# OR WO2004-FR319 OR FR2003
E GENFIT/PA,CS
L2 27 S E3-E13
E DARTEIL/AU
L3 20 S E4-E8
E CAUMONT/AU
L4 11 S E8,E14
E BERTRAND/AU
L5 5 S E3
E BERTRAND K/AU
L6 8 S E3-E5,E7
E NAJIB/AU
L7 33 S E22,E24,E25
SEL RN L1

FILE 'REGISTRY' ENTERED AT 07:29:49 ON 15 AUG 2006

L8 35 S E1-E35
L9 9 S 733010-33-8 OR 733010-35-0 OR 733010-37-2 OR 733010-39-4 OR 7
L10 1 S (733010-33-8 OR 733010-35-0 OR 733010-37-2 OR 733010-39-4 OR
L11 10 S L9,L10
L12 25 S L8 NOT L11
L13 STR
L14 1 S L13
L15 STR L13
L16 0 S L15
L17 SCR 1926 OR 2019
L18 SCR 2021
L19 SCR 1126 OR 1149 OR 1164
L20 SCR 1199 AND 1992
L21 0 S L13 AND (L17 OR L18) AND L19 AND L20
L22 STR L13
L23 25 S L22 AND L20 AND L19 AND (L18 OR L17)
L24 7731 S L22 AND L20 AND L19 AND (L18 OR L17) FUL
SAV L24 KUMAR541/A TEMP
L25 18 S L8 AND L24
L26 8 S L25 NOT L11
L27 5 S L26 NOT (C19H39NO3S OR C15H28N2O5S OR C12H21NO4S2)
L28 15 S L11,L27
L29 8 S L15 SAM SUB=L24
L30 STR L15
L31 7 S L30 SAM SUB=L24
L32 110 S L30 FUL SUB=L24

jan delaval - 15 august 2006

L33 SAV L32 KUMAR541A/A
STR L22
L34 9 S L33 SAM SUB=L24
L35 141 S L33 FUL SUB=L24
SAV L35 KUMAR541B/A
L36 STR
L37 154 S L32 OR L35
L38 1 S L36 SAM SUB=L37
L39 19 S L36 FUL SUB=L37
SAV L39 KUMAR541C/A
L40 135 S L37 NOT L39
L41 120 S L40 NOT L28

FILE 'HCAOLD' ENTERED AT 08:02:34 ON 15 AUG 2006

L42 0 S L28
L43 1 S L41
SEL AN
EDIT E36 /AN /OREF

FILE 'HCAPLUS' ENTERED AT 08:03:57 ON 15 AUG 2006

L44 1 S E36
L45 3 S L28
L46 42 S L41
L47 1 S L44 AND L45,L46
L48 3 S L45 AND L1-L7
L49 2 S L46 AND L1-L7
L50 31 S L46 AND (PD<=20030212 OR PRD<=20030212 OR AD<=20030212)
L51 0 S L41 (L) (THU OR PAC OR PKT OR DMA)/RL AND L50
L52 0 S L41 (L) BAC/RL AND L50
L53 14 S L50 AND (PHARMACEUT? OR PHARMACOL? OR BIOMOL? OR PATHOL? OR C
L54 16 S L50 AND P/DT
L55 24 S L53,L54
L56 7 S L50 NOT L55
SEL HIT RN L50

FILE 'REGISTRY' ENTERED AT 08:08:36 ON 15 AUG 2006

L57 62 S E37-E98
L58 58 S L41 NOT L57
L59 3 S L58 AND (C19H40N2OS2 OR C35H69NO2S4 OR C47H92N2O3S2)

FILE 'HCAOLD' ENTERED AT 08:17:01 ON 15 AUG 2006

L60 0 S L59

FILE 'HCAPLUS' ENTERED AT 08:17:04 ON 15 AUG 2006

L61 2 S L59
L62 4 S L47-L49,L61
L63 4 S L45,L62
SEL RN

FILE 'REGISTRY' ENTERED AT 08:19:24 ON 15 AUG 2006

L64 168 S E99-E266
L65 23 S L64 AND L24
L66 5 S L65 NOT L28,L59

FILE 'REGISTRY' ENTERED AT 08:20:37 ON 15 AUG 2006

FILE 'HCAPLUS' ENTERED AT 08:20:57 ON 15 AUG 2006

FILE 'USPATFULL' ENTERED AT 08:21:32 ON 15 AUG 2006
L67 3 S L59 OR L28

FILE 'USPATFULL' ENTERED AT 08:21:55 ON 15 AUG 2006

=>

8-5/5

PLEASE PRINT CLEARLY

SEARCH REQUEST FORM

(The following text is mirrored bleed-through from the reverse side of the page and is not legible.)

Title of Invention: Acylated aminopropanediols and analogs and
Inventors (please provide full names): Raphael Darteil et al.

Earliest Priority Date: 2/12/03

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

$$\begin{array}{c}
 R^2 - G_2 - \text{CH}_2 - \text{CH}_2 - N(R)R_1 \\
 | \\
 \text{CH}_2 - G_3 - R_3
 \end{array}$$

G_2 & G_3 are $0, 5$ or $\mathbb{N}R^4$, and G_2 & G_3 are not simultaneously $\mathbb{N}R^4$

R & R^4 are H, alkyl

A^1, A^2, A^3 are $H, COH^5, CO(CH_2)_{2n+1}-X-A$

Q5 is alkyl

X is S, Se, SO or SO₂

n is 0-11

R_6 is alkyl etc.

proviso that $G_2 H_2$ and $G_3 H_3$ do not represent OH simultaneously.

Vendors and cost where applicable

Searcher: _____

_____ NA Sequence (#)

✓ STN Dialog

Searcher Phone #: 22504

_____ AA Sequence (#)

_____ Questel/Orbit _____ Lexis/Nexis

Searcher Location: _____

✓ Structure (#)

_____ Westlaw _____ WWW/Internet

Date Searcher Picked Up: 8/18/01

Bibliographic

In-house sequence systems

Date Completed: 8/15/04

Litigation

☐ Commercial ☐ Oligomer ☐ Score/Length
☐ Interference ☐ SPDI ☐ Encode/Transl
 Other (specify) _____

Searcher Prep & Review Time: 20

Fulltext

Online Time: +60

Other